不适合移植的大 B 细胞淋巴瘤二线使用 axicabtagene ciloleucel：ALYCANTE 最终分析
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
一项针对复发/难治性外周 T 细胞淋巴瘤的新抗原激活单倍体相合 T 细胞疗法的 I 期剂量递增研究
英文原题：A phase I dose-escalation study of neoantigen-activated haploidentical T cell therapy for the treatment of relapsed or refractory peripheral T-cell lymphoma.
查看英文原题
A phase I dose-escalation study of neoantigen-activated haploidentical T cell therapy for the treatment of relapsed or refractory peripheral T-cell lymphoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
无标签：外周T细胞淋巴瘤（PTCL）是一种高度异质性的非霍奇金淋巴瘤，预后差且缺乏有效的靶向治疗。过继性T细胞疗法已成功应用于B细胞恶性肿瘤的治疗。我们于2017年首次采用体外经患者特异性新抗原激活的单倍体相合T细胞过继转移治疗一名难治性血管免疫母细胞性T细胞淋巴瘤（AITL）老年患者，该患者实现了长期完全缓解（CR）。在此，我们报告这项首次人体1期临床试验的早期结果，旨在评估新抗原激活的单倍体相合T细胞疗法（NAHTC）对复发/难治性PTCL的安全性和耐受性。临床试验注册：http://www.chictr.org.cn/index.aspx，标识号[ChiCTR1800017440]。
展开英文摘要原文
UNLABELLED: Peripheral T-cell lymphoma (PTCL) is a type of highly heterogeneous non-Hodgkin lymphoma with a poor prognosis and lack of effective targeted therapies. Adoptive T-cell therapy has been successfully used in the treatment of B-cell malignancies.
We first used adoptive transfer of haploidentical T cells activated by patient-specific neoantigens in vitro to treat an elderly patient with refractory angioimmunoblastic T-cell lymphoma (AITL) in 2017, and the patient achieved long-term complete remission (CR).
Here we report on early results from this first-in-human phase 1 clinical trial that aims to assess the safety and tolerability of neoantigen-activated haploidentical T cell therapy (NAHTC) for relapsed/refractory PTCL. CLINICAL TRIAL REGISTRATION: http://www. chictr. org. cn/index. aspx, identifier [ChiCTR1800017440].
论文信息
- 作者
- Chen Y、Zhao H、Luo J、Liao Y、Dan X、Hu G、Gu W
- 第一作者单位
- Department of Hematology, The Affiliated Zhuzhou Hospital Xiangya Medical College CSU, Zhuzhou, Hunan, China.China
- 通讯作者单位
- Chineo Medical Technology Co., Ltd, Beijing, China.China
- 期刊
- Frontiers in oncology2022
- 原文标识
- PubMed 36439517 · DOI 10.3389/fonc.2022.944511
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →